Today, we will review the second quarter 2025 financial results and provide an update on key business trends for Bio-Rad. With me on the call today are Norman Schwartz, our Chief Executive Officer; ...

Ladies and gentlemen, thank you for standing by. My name is Desyree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Bio-Rad First Quarter 2025 ...

Bio-Rad Laboratories (NYSE:BIO) reported first-quarter 2026 results that fell within its revenue guidance range, while management emphasized that geopolitical disruption in the Middle East and continu ...

Q1 2026 Management View Jonathan DiVincenzo (President & COO) said Bio-Rad “reported Q1 results within our revenue guidance” while facing “several external pressures, most notably associated with the ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...

(RTTNews) - Arcutis Biotherapeutics, Inc. (ARQT), on Friday announced it will present five poster presentations at the 2025 Revolutionizing Atopic Dermatitis or RAD Conference, including new long-term ...

Thank you for standing by. My name is Gill, and I will be your operator for today's call. At this time, I would like to welcome each and every one of you to the Bio-Rad Second Quarter 2025 Results ...